Sio Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Sio Capital Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-140,000	Closed	-$2.03M	–	51
2015 Q1	$2.03M	Buy	+140,000	New	+$2.14M	1.15%	19

Other funds holding STML

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sio Capital Management's STML Position: Q2 2015 in Review

Sio Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2015, closing a stake of 140,000 shares — an estimated $2.03M sold.

Sio Capital Management first reported a position in STML in Q1 2015 and held it in 1 quarter. The position peaked at $2.03M in Q1 2015. 71 funds tracked by Wall St. Rank hold STML as of Q2 2015.

Sio Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Sio Capital Management sold 140,000 Stemline Therapeutics, Inc. shares in Q2 2015, an estimated $2.03M.
Sio Capital Management first reported a position in Stemline Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
Sio Capital Management's Stemline Therapeutics, Inc. position peaked at $2.03M in Q1 2015.
71 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2015.

Based on Sio Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.